Terkko Navigator / Remitz, A(nita)*

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.

Position statement: topical calcineurin inhibitors in atopic dermatitis.

The Value of Filaggrin Null Mutations in Predicting Treatment Response in Atopic Dermatitis: An Observational Study in Finnish Patients.

High Serum Total IgE Predicts Poor Long-term Outcome in Atopic Dermatitis.

An update on current pharmacotherapy options in atopic dermatitis.

Long-term Safety of Topical Pimecrolimus and Topical Tacrolimus in Atopic Blepharoconjunctivitis.

Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study.

Tacrolimus ointment in atopic blepharoconjunctivitis does not seem to elevate intraocular pressure.

Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis.

A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years.

One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial.